Delivery Order SPE2DB20D3103-SPE2DB25FP8T9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $17,103.34 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's established capability to compete in open...
- The Defense Logistics Agency awarded a delivery order valued at $11,105.00 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a single shipment of pharmaceutical product to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $25,054.58 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $19,081.06 for Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,059.35 on September 15, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open procurement. The contract is set to be completed by September 16, 2025, and performance will occur at the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $47,262.06 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete openly for...
- The Defense Logistics Agency awarded a delivery order valued at $11,053.94 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order transaction under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8T9Delivery Order
The Defense Logistics Agency awarded a $34,661.18 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems globally. The delivery of Dupixent, a biologic immunosuppressant medication used primarily for atopic dermatitis and other inflammatory conditions, represents one of many pharmaceutical products delivered under this extensive federal contract vehicle supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.7k | 8/14/25 |